Nexium Capsules LDA Specific Clinical Experience Investigation

AstraZeneca

Status: Completed

Conditions: Gastric Ulcer; Duodenal Ulcer

Study type: Observational

Funder types: Industry

Identifiers

NCT01729182

D961PC00002

Details and patient eligibility

About

The purpose of this investigation is to collect following data in patients given Nexium capsule (Nexium) for long term in usual-post-marketing therapy to prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Full description

Nexium capsules Specific Clinical Experience Investigation for long-term use concerning prevention of recurrence of gastric ulcer or duodenal ulcer with Low dose Aspirin (LDA).

Enrollment: 2,363 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Exclusion Criteria:

• Patients having gastric ulcer/duodenal ulcer when Nexium is started (Active phase (A1, A2) or healing phase (H1, H2) of Sakita-Miwa classification on endoscopy).
• Patients who had been given Nexium for suppression of recurrence of gastric ulcer/duodenal ulcer.

Trial design

2,363 participants in 1 patient group

Nexium